Neuland Laboratories Ltd saw its shares rally more than 7% in early trade on Monday after the company delivered a strong set of numbers for the July–September quarter (Q2 FY25). The Hyderabad-based pharmaceutical company reported impressive growth across all key metrics, reflecting robust business momentum and operational efficiency. As of 9:29 AM, the shares were trading 5.15% higher at Rs 18,756.00.
For the quarter ended September 2025, Neuland Labs’ revenue soared 65.4% year-on-year to Rs 514 crore, compared to Rs 311 crore in the same quarter last year. The sharp rise was driven by strong demand across both the API (Active Pharmaceutical Ingredients) and specialty segments.
Operating performance also showed remarkable improvement. EBITDA jumped to Rs 156 crore from Rs 62.2 crore, marking a surge of 150% YoY. The EBITDA margin expanded sharply to 30.2% from 20% in the previous year, indicating better cost control and a favorable product mix.
The company’s net profit soared nearly threefold to Rs 96.9 crore, compared to Rs 32.8 crore in the year-ago period.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
